Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Preventive Vaccines Market Expected To Reach $131.26 Billion By 2030 At 9.8% CAGR
The market for preventive vaccines has experienced robust expansion over the past few years. Its value is projected to rise from $83 billion in 2025 to $90.33 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.8%. This historic period’s growth was largely driven by efforts to eradicate and manage infectious diseases, vaccination programs spearheaded by governments, heightened public awareness of health issues, the creation of worldwide immunization campaigns, and greater financial support from global health organizations.
The preventive vaccines market is projected to experience robust expansion over the coming years, reaching an estimated value of $131.27 billion by 2030, with a compound annual growth rate (CAGR) of 9.8%. This anticipated growth during the forecast period is driven by factors such as the advancement of next-generation vaccine technologies, a growing global population coupled with urban expansion, heightened initiatives aimed at outbreak preparedness, the broadening of adult immunization programs, and a rise in collaborative efforts between public and private sectors in vaccine development. Key trends shaping the market outlook include the widening reach of national immunization campaigns, an increased emphasis on preventive healthcare and disease management, a greater need for vaccines targeting children and the elderly, the development of combination and multivalent vaccines, and improvements in cold chain logistics and storage infrastructure.
Download A Free Sample Report For Comprehensive Market Insights:
Preventive Vaccines Market Opportunity Drivers: What Is Creating New Revenue Potential?
The anticipated expansion of the preventive vaccines market is set to be driven by the growing frequency of infectious diseases. These diseases are caused by pathogenic microorganisms like bacteria, viruses, fungi, or parasites, which can spread between individuals or via environmental factors. Their rising occurrence is fueled by accelerating urbanization, global travel, and antimicrobial resistance, which speed up transmission and complicate containment efforts. Preventive vaccines combat these conditions by priming the immune system to detect and attack pathogens prior to infection, thus lowering case numbers and interrupting spread. As an example, the 2024 report from the World Health Organization, a Switzerland-based intergovernmental body, indicated that newly diagnosed tuberculosis (TB) cases worldwide hit 8.2 million in 2023, up from 7.5 million the previous year. Consequently, the heightened incidence of infectious diseases is fueling growth in the preventive vaccines market.
Preventive Vaccines Market Segment Landscape: Which Areas Lead Market Development?
The preventive vaccines market covered in this report is segmented –
1) By Type: Live Or Attenuated Vaccines, Inactivated Vaccines, Toxoid Vaccines, Subunit Vaccines, Conjugate Vaccines, DNA Vaccines, Recombinant Vector Vaccines
2) By Disease Type: Pneumococcal, Poliovirus, Hepatitis, Influenza, Measles, Rubella, Other Disease Types
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Other Distribution Channels
Subsegments:
1) By Live or Attenuated Vaccines: Measles, Mumps, and Rubella (MMR) Vaccine, Varicella (Chickenpox) Vaccine, Oral Polio Vaccine (OPV), Yellow Fever Vaccine, Rotavirus Vaccine, Bacillus Calmette-Guérin (BCG) Vaccine
2) By Inactivated Vaccines: Inactivated Poliovirus Vaccine (IPV), Hepatitis A Vaccine, Rabies Vaccine, Influenza (Inactivated) Vaccine, Japanese Encephalitis Vaccine
3) By Toxoid Vaccines: Tetanus Toxoid Vaccine, Diphtheria Toxoid Vaccine, Pertussis (whooping cough) Vaccine
4) By Subunit Vaccines: Hepatitis B Vaccine, Human Papillomavirus (HPV) Vaccine, Pertussis (acellular) Vaccine, Influenza (recombinant protein) Vaccine
5) By Conjugate Vaccines: Pneumococcal Conjugate Vaccine (PCV), Haemophilus influenzae type b (Hib) Vaccine, Meningococcal Conjugate Vaccine
6) By DNA Vaccines: Zika Virus DNA Vaccine, Cytomegalovirus (CMV) DNA Vaccine, Infectious Disease DNA Vaccines
7) By Recombinant Vector Vaccines: Ebola Vaccine (rVSV-ZEBOV), COVID-19 Recombinant Vector Vaccines, Dengue Recombinant Vector Vaccines
Preventive Vaccines Market Innovation Trends Driving Future Development
Leading players in the preventive vaccines market are increasingly investing in innovative vaccine technologies, particularly advanced mRNA platforms, to boost efficacy, improve safety, simplify storage requirements, accelerate production timelines, and offer expanded protection against new strains of infectious diseases. These advanced mRNA platforms utilize messenger RNA to direct cells in generating specific proteins, which in turn prompts a precise immune reaction. A notable example occurred in March 2025, when Moderna Inc., a biotechnology firm based in the United States, secured FDA approval for mRNA-1283, marketed as mNEXSPIKE, a novel COVID-19 vaccine. This vaccine is approved for adults aged 65 and older, as well as individuals between 12 and 64 years old who have at least one risk factor identified by the CDC. The introduction of mNEXSPIKE represents a major milestone in next-generation mRNA vaccine development, featuring enhanced stability and simpler storage conditions relative to previous formulations. Consequently, this breakthrough is anticipated to improve vaccine availability and distribution, especially in underserved and isolated regions.
Preventive Vaccines Market Industry Leaders And Market Competition
Major companies operating in the preventive vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Sanofi Pasteur SA, AstraZeneca plc, GlaxoSmithKline plc (GSK), Takeda Pharmaceutical Company Limited, Moderna Inc., CSL Limited, Novavax Inc., Emergent BioSolutions Inc., Dynavax Technologies Corporation, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., Bavarian Nordic A/S, Valneva SE, Panacea Biotec Ltd., Inovio Pharmaceuticals Inc., Mitsubishi Tanabe Pharma Corporation, Afrigen Biologics and Vaccines (Pty) Ltd.
Access The Complete Preventive Vaccines Market Report:
Preventive Vaccines Market Regional Analysis: Which Region Leads By Revenue?
North America was the largest region in the preventive vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the preventive vaccines market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model